SOPHiA GENETICS (SOPH) Q2 2026 Earnings Call Transcript
SOPHiA GENETICS SA (SOPH) reported Q2 2026 revenue of $23.3 million, up 27%, and an adjusted EBITDA loss of $8.8 million. Platform analysis volume rose 22% to 115,000 patient analyses. Management raised full-year revenue guidance to $94 million to $96 million and reaffirmed adjusted EBITDA loss of $29 million to $32 million, citing U.S. in-house testing demand and biopharma growth.
How this was made
The 30-second read
Why it matters
Traders can update expectations for 2026 revenue and operating leverage based on raised full-year revenue guidance, Q2 margin dynamics, and reaffirmed adjusted EBITDA loss range.
Market read
The call provides concrete operating metrics (platform analyses, liquid biopsy customer adds, net dollar retention) plus updated financial guidance that can drive repricing.
What to watch
Patent litigation expenses (net $1.1M in Q2) and the mix shift toward lower-margin biopharma and services could continue to cap margin recovery even as volumes grow.
Background
SOPHiA GENETICS held its Q2 2026 earnings call, detailing platform usage growth, liquid biopsy expansion, and progress toward EBITDA breakeven.
Ticker impact
SOPHiA reported Q2 revenue of $23.3M, raised full-year revenue guidance to $94M-$96M, and reaffirmed adjusted EBITDA loss guidance.
Bias toward near-term upside on guidance raise, tempered by continued adjusted EBITDA losses and gross margin decline.
The article discloses multiple decision-relevant datapoints: raised revenue guidance, Q2 growth drivers (platform volume, liquid biopsy customers), and a reaffirmed EBITDA loss range despite margin softness.
Market effects
Signals continued demand strength in genomic diagnostics and liquid biopsy, with management emphasizing AI productivity and biopharma/CDx partnership momentum.
Highlights Asia Pacific revenue growth (31%) and volume expansion, which may support regional sentiment for precision oncology testing demand.
Reinforces the broader precision oncology ecosystem theme of scaling platform-based evidence generation and companion diagnostic collaborations.
Counterpoint
Despite the revenue beat and guidance raise, adjusted gross margin fell (72.1% vs 74.4%), and adjusted EBITDA loss guidance remains sizable, suggesting profitability progress may be slower than the revenue narrative implies.
Key entities
- companySOPHiA GENETICS SA
Reported Q2 2026 results and guidance, including raised full-year revenue outlook and reaffirmed adjusted EBITDA loss range.
- partnerAstraZeneca
Announced first two companion diagnostic programs with SOPHiA, described as SOPHiA's first CDx wins.
- partnerMemorial Sloan Kettering
Memorandum of understanding for a joint venture to build an AI lab of the future in New York City.
- litigation counterpartGuardant Health
Referenced in UK and France patent infringement defense costs tied to ongoing litigation.
